[
    [
        {
            "time": "",
            "original_text": "乐普医疗(300003.SZ)截至6月底累计回购2.54亿元的股份",
            "features": {
                "keywords": [
                    "乐普医疗",
                    "回购",
                    "股份"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "乐普医疗(300003.SZ)截至6月底累计回购2.54亿元的股份",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "盘后8公司发回购公告-更新中",
            "features": {
                "keywords": [
                    "回购",
                    "公告"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "盘后8公司发回购公告-更新中",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医疗保健：制剂原料一体化企业将受益 荐3股",
            "features": {
                "keywords": [
                    "医疗保健",
                    "制剂原料",
                    "一体化",
                    "受益"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗保健"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医疗保健：制剂原料一体化企业将受益 荐3股",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【东吴医药】医药生物行业2019H1业绩总结：行业增速放缓，龙头引领增长，聚焦创新药产业链、创新生物制品、医疗服务等景气细分赛道",
            "features": {
                "keywords": [
                    "医药生物",
                    "行业增速",
                    "放缓",
                    "龙头",
                    "创新药",
                    "产业链"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【东吴医药】医药生物行业2019H1业绩总结：行业增速放缓，龙头引领增长，聚焦创新药产业链、创新生物制品、医疗服务等景气细分赛道",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【异动股】人脑工程板块下挫，冠昊生物(300238-CN)跌3.41%",
            "features": {
                "keywords": [
                    "人脑工程",
                    "板块下挫",
                    "冠昊生物",
                    "跌幅"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "人脑工程"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【异动股】人脑工程板块下挫，冠昊生物(300238-CN)跌3.41%",
                "Correlation": 4,
                "Sentiment": 3,
                "Importance": 5,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "4+7扩面第二天：恒瑞、石药、齐鲁跌破4+7价格",
            "features": {
                "keywords": [
                    "4+7扩面",
                    "恒瑞",
                    "石药",
                    "齐鲁",
                    "跌破",
                    "价格"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "4+7扩面第二天：恒瑞、石药、齐鲁跌破4+7价格",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "晨会聚焦190904重点关注计算机行业",
            "features": {
                "keywords": [
                    "晨会聚焦",
                    "计算机行业"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "计算机"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "晨会聚焦190904重点关注计算机行业",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "9月4日券商晨会研报汇编",
            "features": {
                "keywords": [
                    "券商晨会",
                    "研报汇编"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "9月4日券商晨会研报汇编",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "乐普医疗深度报告:创新为乐,普济天下",
            "features": {
                "keywords": [
                    "乐普医疗",
                    "深度报告",
                    "创新"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "乐普医疗深度报告:创新为乐,普济天下",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]